BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663-1671. [PMID: 18420499 DOI: 10.1056/nejmoa0707056] [Cited by in Crossref: 617] [Cited by in F6Publishing: 207] [Article Influence: 47.5] [Reference Citation Analysis]
Number Citing Articles
1 Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K, Watanabe T, Hausheer FH. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 2012;20:3355-64. [PMID: 22584733 DOI: 10.1007/s00520-012-1492-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 6.2] [Reference Citation Analysis]
2 Kulkarni SA, Hicks DG, Watroba NL, Murekeyisoni C, Hwang H, Khoury T, Beck RA, Ring BZ, Estopinal NC, Schreeder MT, Seitz RS, Ross DT. TLE3 as a candidate biomarker of response to taxane therapy. Breast Cancer Res 2009;11:R17. [PMID: 19309506 DOI: 10.1186/bcr2241] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
3 Paluch-Shimon S, Cherny NI, de Vries EGE, Dafni U, Piccart MJ, Latino NJ, Cardoso F. Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. ESMO Open 2020;5:e000743. [PMID: 32893189 DOI: 10.1136/esmoopen-2020-000743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Alken S, Kelly CM. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. Cancer Manag Res 2013;5:357-65. [PMID: 24143122 DOI: 10.2147/CMAR.S49321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
5 Koppold-Liebscher D, Kessler CS, Steckhan N, Bähr V, Kempter C, Wischnewsky M, Hübner M, Kunz B, Paul M, Zorn S, Sari S, Jeitler M, Stange R, Michalsen A. Short-term fasting accompanying chemotherapy as a supportive therapy in gynecological cancer: protocol for a multicenter randomized controlled clinical trial. Trials 2020;21:854. [PMID: 33059765 DOI: 10.1186/s13063-020-04700-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Timmins HC, Li T, Trinh T, Kiernan MC, Harrison M, Boyle F, Friedlander M, Goldstein D, Park SB. Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. Oncologist 2021;26:366-74. [PMID: 33523545 DOI: 10.1002/onco.13697] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CL. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 2012;20:1991-7. [PMID: 22089428 DOI: 10.1007/s00520-011-1303-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Sarosy GA, Hussain MM, Seiden MV, Fuller AF, Nikrui N, Goodman A, Minasian L, Reed E, Steinberg SM, Kohn EC. Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer. Cancer 2010;116:1476-84. [PMID: 20091841 DOI: 10.1002/cncr.24861] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
9 Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, Pins M, Yang X, Sledge GW. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat 2010;119:663-71. [PMID: 20012354 DOI: 10.1007/s10549-009-0658-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
10 Legakis LP, Bigbee JW, Negus SS. Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity. Behav Pharmacol 2018;29:290-8. [PMID: 29369054 DOI: 10.1097/FBP.0000000000000378] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
11 Isacoff WH, Reber HA, Bedford R, Hoos W, Rahib L, Upfill-Brown A, Donahue T, Hines OJ. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Target Oncol 2018;13:461-8. [PMID: 29882102 DOI: 10.1007/s11523-018-0572-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
12 King KM, Lupichuk S, Baig L, Webster M, Basi S, Whyte D, Rix S. Optimal use of taxanes in metastatic breast cancer. Curr Oncol 2009;16:8-20. [PMID: 19526080 DOI: 10.3747/co.v16i3.377] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
13 Walker LG, Eremin JM, Aloysius MM, Vassanasiri W, Walker MB, El-Sheemy M, Cowley G, Beer J, Samphao S, Wiseman J, Jibril JA, Valerio D, Clarke DJ, Kamal M, Thorpe GW, Baria K, Eremin O. Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer 2011;11:179. [PMID: 21592370 DOI: 10.1186/1471-2407-11-179] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
14 Schmidt M. Chemotherapy in early breast cancer: when, how and which one? Breast Care (Basel) 2014;9:154-60. [PMID: 25177256 DOI: 10.1159/000363755] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kim SS, Klemp J, Fabian C. Breast cancer and fertility preservation. Fertil Steril 2011;95:1535-43. [PMID: 21272867 DOI: 10.1016/j.fertnstert.2011.01.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
16 Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat 2013;138:457-66. [PMID: 23423445 DOI: 10.1007/s10549-013-2416-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 7.3] [Reference Citation Analysis]
17 Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 2009;11:R9. [PMID: 19228416 DOI: 10.1186/bcr2225] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]
18 Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, Lu Z, Bast RC Jr, Feng Y, Yu Y. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer 2011;11:22. [PMID: 21244707 DOI: 10.1186/1471-2407-11-22] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
19 Morris PG, Hudis CA. Optimizing dose-dense regimens for early-stage breast cancer. Nat Rev Clin Oncol 2010;7:678-9. [PMID: 21116238 DOI: 10.1038/nrclinonc.2010.188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
20 Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS;  ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101:1174-1181. [PMID: 19657108 DOI: 10.1093/jnci/djp235] [Cited by in Crossref: 150] [Cited by in F6Publishing: 124] [Article Influence: 12.5] [Reference Citation Analysis]
21 Bai Z, Zhang Z, Qu X, Han W, Ma X. Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1. Oncol Lett 2012;3:135-40. [PMID: 22740869 DOI: 10.3892/ol.2011.416] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
22 Dackus GMHE, Jóźwiak K, van der Wall E, van Diest PJ, Hauptmann M, Siesling S, Sonke GS, Linn SC. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. Breast Cancer Res Treat 2021;185:817-30. [PMID: 33113088 DOI: 10.1007/s10549-020-05978-8] [Reference Citation Analysis]
23 Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106-116. [PMID: 26175926 DOI: 10.7497/j.issn.2095-3941.2015.0030] [Cited by in F6Publishing: 148] [Reference Citation Analysis]
24 Dawood S. Triple-negative breast cancer: epidemiology and management options. Drugs 2010;70:2247-58. [PMID: 21080741 DOI: 10.2165/11538150-000000000-00000] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
25 de Almeida FK, Rosa DD. Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates. Breast Care (Basel) 2018;13:447-52. [PMID: 30800040 DOI: 10.1159/000488026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Stan D, Loprinzi CL, Ruddy KJ. Breast cancer survivorship issues. Hematol Oncol Clin North Am 2013;27:805-27, ix. [PMID: 23915746 DOI: 10.1016/j.hoc.2013.05.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
27 Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL. Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clin Cancer Res 2018;24:3602-10. [PMID: 29703818 DOI: 10.1158/1078-0432.CCR-18-0656] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 7.3] [Reference Citation Analysis]
28 Rampurwala MM, Rocque GB, Burkard ME. Update on adjuvant chemotherapy for early breast cancer. Breast Cancer (Auckl) 2014;8:125-33. [PMID: 25336961 DOI: 10.4137/BCBCR.S9454] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
29 Kemp Z, Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health 2013;5:45-51. [PMID: 23378788 DOI: 10.2147/IJWH.S30231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
30 Brami C, Bao T, Deng G. Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review. Crit Rev Oncol Hematol 2016;98:325-34. [PMID: 26652982 DOI: 10.1016/j.critrevonc.2015.11.014] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
31 Sahni JM, Keri RA. Targeting bromodomain and extraterminal proteins in breast cancer. Pharmacol Res 2018;129:156-76. [PMID: 29154989 DOI: 10.1016/j.phrs.2017.11.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
32 Suzuki Y, Saeki T, Aogi K, Toi M, Fujii H, Inoue K, Watanabe T, Fujiwara Y, Ito Y, Takatsuka Y, Iwata H, Arioka H, Tokuda Y. A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. Int J Clin Oncol 2013;18:590-7. [PMID: 22585426 DOI: 10.1007/s10147-012-0421-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Yu KD, Liu GY, Chen CM, Li JW, Wu J, Lu JS, Shen ZZ, Shao ZM. Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule. Oncologist 2013;18:511-7. [PMID: 23635560 DOI: 10.1634/theoncologist.2012-0057] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
34 Nuzzo F, Morabito A, Gravina A, Di Rella F, Landi G, Pacilio C, Labonia V, Rossi E, De Maio E, Piccirillo MC, D'Aiuto G, Thomas R, Rinaldo M, Botti G, Di Bonito M, Di Maio M, Gallo C, Perrone F, de Matteis A. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. BMC Cancer 2011;11:75. [PMID: 21324184 DOI: 10.1186/1471-2407-11-75] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
35 Swaroop MN, Ferguson CM, Horick NK, Skolny MN, Miller CL, Jammallo LS, Brunelle CL, O'Toole JA, Isakoff SJ, Specht MC, Taghian AG. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat 2015;151:393-403. [PMID: 25940996 DOI: 10.1007/s10549-015-3408-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
36 Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res Treat 2016;156:453-64. [PMID: 27013473 DOI: 10.1007/s10549-016-3759-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 7.6] [Reference Citation Analysis]
37 Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer 2009;17:1071-80. [PMID: 19089463 DOI: 10.1007/s00520-008-0550-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
38 Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8:1913-24. [PMID: 27765921 DOI: 10.18632/oncotarget.12284] [Cited by in Crossref: 143] [Cited by in F6Publishing: 127] [Article Influence: 47.7] [Reference Citation Analysis]
39 Huehnchen P, Boehmerle W, Endres M. Assessment of paclitaxel induced sensory polyneuropathy with "Catwalk" automated gait analysis in mice. PLoS One 2013;8:e76772. [PMID: 24143194 DOI: 10.1371/journal.pone.0076772] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
40 Fratz EJ, Hunter GA, Ferreira GC. Expression of murine 5-aminolevulinate synthase variants causes protoporphyrin IX accumulation and light-induced mammalian cell death. PLoS One 2014;9:e93078. [PMID: 24718052 DOI: 10.1371/journal.pone.0093078] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
41 Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother 2015;16:983-98. [PMID: 25881743 DOI: 10.1517/14656566.2015.1032246] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
42 Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61. [PMID: 20164691 DOI: 10.1097/PPO.0b013e3181d24ff7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 105] [Article Influence: 16.7] [Reference Citation Analysis]
43 Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 2012;134:401-10. [PMID: 22527101 DOI: 10.1007/s10549-012-2054-0] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]
44 Burgess M, Puhalla S. BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. Front Oncol 2014;4:19. [PMID: 24579064 DOI: 10.3389/fonc.2014.00019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
45 Kawajiri H, Takashima T, Onoda N, Kashiwagi S, Noda S, Ishikawa T, Wakasa K, Hirakawa K. Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer. Oncol Lett 2012;4:612-6. [PMID: 23205071 DOI: 10.3892/ol.2012.801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
46 Giri M, Giri M, Thapa RJ, Upreti B, Pariyar B. Breast Cancer in Nepal: Current status and future directions. Biomed Rep 2018;8:325-9. [PMID: 29541453 DOI: 10.3892/br.2018.1057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
47 Tanabe Y, Shiraishi S, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y, Shimizu C. Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. BMC Cancer 2020;20:325. [PMID: 32295642 DOI: 10.1186/s12885-020-06834-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med 2015;13:195. [PMID: 26278220 DOI: 10.1186/s12916-015-0439-8] [Cited by in Crossref: 134] [Cited by in F6Publishing: 114] [Article Influence: 22.3] [Reference Citation Analysis]
49 Yu KD, Liu XY, Chen L, Mo M, Wu J, Liu GY, Di GH, Verschraegen C, Stover DG, Zhuang ZG, Bertucci F, Orlandi A, Wang J, Lippi G, Wu KJ, Osman MA, Fan L, Shao ZM. Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. Lancet Reg Health West Pac 2021;11:100158. [PMID: 34327363 DOI: 10.1016/j.lanwpc.2021.100158] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Comen E, Morris PG, Norton L. Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer. J Mammary Gland Biol Neoplasia 2012;17:241-9. [PMID: 23011603 DOI: 10.1007/s10911-012-9267-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
51 Lu D, Joshi A, Li H, Zhang N, Ren MM, Gao Y, Wada R, Jin JY. Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients. CPT Pharmacometrics Syst Pharmacol 2014;3:e115. [PMID: 24850445 DOI: 10.1038/psp.2014.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
52 de Gregorio A, Häberle L, Fasching PA, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl TWP, Bauer E, de Gregorio N, Deniz M, Fink V, Bekes I, Andergassen U, Schneeweiss A, Tesch H, Mahner S, Brucker SY, Blohmer JU, Fehm TN, Heinrich G, Lato K, Beckmann MW, Rack B, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res 2020;22:111. [PMID: 33097092 DOI: 10.1186/s13058-020-01348-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
53 Xu B, Shao Z, Wang S, Jiang Z, Hu X, Zhang X, Li X, Liu J, Li M, Wang S. Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies. Chin J Cancer Res 2018;30:327-39. [PMID: 30046227 DOI: 10.21147/j.issn.1000-9604.2018.03.05] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Shinde SS, Seisler D, Soori G, Atherton PJ, Pachman DR, Lafky J, Ruddy KJ, Loprinzi CL. Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial. Support Care Cancer 2016;24:547-53. [PMID: 26155765 DOI: 10.1007/s00520-015-2807-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
55 Shieh MP, Mehta RS. Oligohydramnios associated with administration of weekly paclitaxel for triple-negative breast cancer during pregnancy. Ann Oncol 2011;22:2151-2. [PMID: 21799203 DOI: 10.1093/annonc/mdr339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
56 Jimenez P, Pathak A, Phan AT. The role of taxanes in the management of gastroesphageal cancer. J Gastrointest Oncol 2011;2:240-9. [PMID: 22811858 DOI: 10.3978/j.issn.2078-6891.2011.027] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
57 Lee HJ, Heo DS, Cho JY, Han SW, Chang HJ, Yi HG, Kim TE, Lee SH, Oh DY, Im SA, Jang IJ, Bang YJ. A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer. Cancer Res Treat 2014;46:234-42. [PMID: 25038758 DOI: 10.4143/crt.2014.46.3.234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
58 Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat 2011;127:153-62. [PMID: 21350820 DOI: 10.1007/s10549-011-1413-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
59 Li Q, Wang J, Mu Y, Zhang T, Han Y, Wang J, Li Q, Luo Y, Ma F, Fan Y, Zhang P, Xu B. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chin J Cancer Res 2020;32:485-96. [PMID: 32963461 DOI: 10.21147/j.issn.1000-9604.2020.04.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Kin T, Ohtani S, Maeda R, Ueno A, Fujihara M, Takamatsu Y, Kajiwara Y, Ito M, Kawasaki K, Abe K, Sakata Y, Hiraki K. Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial. World J Oncol 2020;11:197-203. [PMID: 33117463 DOI: 10.14740/wjon1333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Conde J, Oliva N, Atilano M, Song HS, Artzi N. Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment. Nat Mater 2016;15:353-63. [PMID: 26641016 DOI: 10.1038/nmat4497] [Cited by in Crossref: 149] [Cited by in F6Publishing: 118] [Article Influence: 24.8] [Reference Citation Analysis]
62 Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2020;6:1390-6. [PMID: 32789480 DOI: 10.1001/jamaoncol.2020.2965] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
63 Shimizu H, Takeishi S, Nakatsumi H, Nakayama KI. Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells. JCI Insight 2019;4:125138. [PMID: 30830867 DOI: 10.1172/jci.insight.125138] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
64 Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432-444. [PMID: 22152853 DOI: 10.1016/s0140-6736(11)61625-5] [Cited by in Crossref: 1167] [Cited by in F6Publishing: 511] [Article Influence: 116.7] [Reference Citation Analysis]
65 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
66 Sundar R, Jeyasekharan AD, Pang B, Soong RC, Kumarakulasinghe NB, Ow SG, Ho J, Lim JS, Tan DS, Wilder-Smith EP, Bandla A, Tan SS, Asuncion BR, Fazreen Z, Hoppe MM, Putti TC, Poh LM, Goh BC, Lee SC. Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy. PLoS One 2016;11:e0164319. [PMID: 27716814 DOI: 10.1371/journal.pone.0164319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
67 Crawford S. Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front Pharmacol 2013;4:68. [PMID: 23805101 DOI: 10.3389/fphar.2013.00068] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
68 Tamura K, Inoue K, Masuda N, Takao S, Kashiwaba M, Tokuda Y, Iwata H, Yamamoto N, Aogi K, Saeki T, Nakayama T, Sato N, Toyama T, Ishida T, Arioka H, Saito M, Ohno S, Yamauchi H, Yamada K, Watanabe J, Ishiguro H, Fujiwara Y. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Sci 2017;108:987-94. [PMID: 28256066 DOI: 10.1111/cas.13221] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
69 Yoo KE, Kang RY, Lee JY, Lee YJ, Suh SY, Kim KS, Kim HS, Lee SH, Lee BK. Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy. Support Care Cancer. 2015;23:1969-1977. [PMID: 25500718 DOI: 10.1007/s00520-014-2547-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
70 Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol 2011;18:180-90. [PMID: 21874117 DOI: 10.3747/co.v18i4.913] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
71 Andreopoulou E, Sparano JA. Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview. Curr Breast Cancer Rep 2013;5:42-50. [PMID: 23440080 DOI: 10.1007/s12609-012-0097-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
72 Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013;15:R88. [PMID: 24063698 DOI: 10.1186/bcr3484] [Cited by in Crossref: 123] [Cited by in F6Publishing: 111] [Article Influence: 17.6] [Reference Citation Analysis]
73 Qin YY, Li H, Guo XJ, Ye XF, Wei X, Zhou YH, Zhang XJ, Wang C, Qian W, Lu J, He J. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One 2011;6:e26946. [PMID: 22069477 DOI: 10.1371/journal.pone.0026946] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
74 Aribi A, Gery S, Lee DH, Thoennissen NH, Thoennissen GB, Alvarez R, Ho Q, Lee K, Doan NB, Chan KT, Toh M, Said JW, Koeffler HP. The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. Int J Cancer 2013;132:2730-7. [PMID: 23165325 DOI: 10.1002/ijc.27950] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
75 Della Pepa C, Tonini G, Pisano C, Di Napoli M, Cecere SC, Tambaro R, Facchini G, Pignata S. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer 2015;34:17-27. [PMID: 25556615 DOI: 10.5732/cjc.014.10274] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
76 Kotani H, Terada M, Mori M, Horisawa N, Sugino K, Kataoka A, Adachi Y, Gondou N, Yoshimura A, Hattori M, Sawaki M, Takahata C, Kobara M, Iwata H. Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial. BMC Cancer 2021;21:548. [PMID: 33985457 DOI: 10.1186/s12885-021-08240-6] [Reference Citation Analysis]
77 Obeng-Gyasi S, O'Neill A, Zhao F, Kircher SM, Lava TR, Wagner LI, Miller KD, Sparano JD, Sledge GW, Carlos RC. Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer. Cancer Med 2021;10:45-52. [PMID: 33264502 DOI: 10.1002/cam4.3542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
79 Chae HK, Yang JI, An JH, Lee IH, Son MH, Song WJ, Youn HY. Use of oral paclitaxel for the treatment of bladder tumors in dogs. J Vet Med Sci 2020;82:527-30. [PMID: 32249251 DOI: 10.1292/jvms.19-0578] [Reference Citation Analysis]
80 Kim CG, Sohn J, Chon H, Kim JH, Heo SJ, Cho H, Kim IJ, Kim SI, Park S, Park HS, Kim GM. Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. J Breast Cancer 2016;19:76-82. [PMID: 27064666 DOI: 10.4048/jbc.2016.19.1.76] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
81 Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol 2010;7:139-47. [PMID: 20125090 DOI: 10.1038/nrclinonc.2009.234] [Cited by in Crossref: 120] [Cited by in F6Publishing: 97] [Article Influence: 10.9] [Reference Citation Analysis]
82 Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 2015;23:2019-24. [PMID: 25519756 DOI: 10.1007/s00520-014-2556-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
83 Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol 2014;32:1620-9. [PMID: 24711558 DOI: 10.1200/JCO.2013.53.0204] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 5.6] [Reference Citation Analysis]
84 Chan JK, Chow S, Bhowmik S, Mann A, Kapp DS, Coleman RL. Metastatic gynecologic malignancies: advances in treatment and management. Clin Exp Metastasis 2018;35:521-33. [PMID: 29931499 DOI: 10.1007/s10585-018-9889-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
85 Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 2012;104:406-14. [PMID: 22250182 DOI: 10.1093/jnci/djr543] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 6.4] [Reference Citation Analysis]
86 Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012;30:2232-2239. [PMID: 22614988 DOI: 10.1200/jco.2011.40.1273] [Cited by in Crossref: 118] [Cited by in F6Publishing: 57] [Article Influence: 13.1] [Reference Citation Analysis]
87 Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski R. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer 2013;21:2679-86. [PMID: 23686402 DOI: 10.1007/s00520-013-1842-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
88 Sánchez-Barroso L, Apellaniz-Ruiz M, Gutiérrez-Gutiérrez G, Santos M, Roldán-Romero JM, Curras M, Remacha L, Calsina B, Calvo I, Sereno M, Merino M, García-Donas J, Castelo B, Guerra E, Letón R, Montero-Conde C, Cascón A, Inglada-Pérez L, Robledo M, Rodríguez-Antona C. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy. Oncologist 2019;24:e784-92. [PMID: 30470691 DOI: 10.1634/theoncologist.2018-0418] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
89 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 94] [Article Influence: 19.4] [Reference Citation Analysis]
90 Mirzaei HR, Sabet Rasekh P, Nasrollahi F, Sabet Rasekh P, Akbari Tirabad Z, Moein HR, Ghaffari Pour T, Hajian P. Dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node-positive breast cancer. Int J Breast Cancer 2013;2013:404396. [PMID: 24187626 DOI: 10.1155/2013/404396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Lin Q, He Y, Wang X, Zhang Y, Hu M, Guo W, He Y, Zhang T, Lai L, Sun Z, Yi Z, Liu M, Chen Y. Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression. Adv Sci (Weinh) 2020;7:1903483. [PMID: 32382484 DOI: 10.1002/advs.201903483] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
92 Fitzpatrick A, Tutt A. Controversial issues in the neoadjuvant treatment of triple-negative breast cancer. Ther Adv Med Oncol 2019;11:1758835919882581. [PMID: 31700549 DOI: 10.1177/1758835919882581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
93 Greenlee H, Hershman DL, Shi Z, Kwan ML, Ergas IJ, Roh JM, Kushi LH. BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study. J Natl Cancer Inst. 2017;109. [PMID: 27794123 DOI: 10.1093/jnci/djw206] [Cited by in Crossref: 54] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
94 Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 2017;35:2647-55. [PMID: 28398846 DOI: 10.1200/JCO.2016.71.4147] [Cited by in Crossref: 109] [Cited by in F6Publishing: 52] [Article Influence: 27.3] [Reference Citation Analysis]
95 Schuetz F. Adjuvant Systemic Therapy of Breast Cancer. Breast Care (Basel) 2011;6:179-83. [PMID: 21779222 DOI: 10.1159/000329336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
96 Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics 2015;33:179-90. [PMID: 25404424 DOI: 10.1007/s40273-014-0227-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
97 Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016;374:738-748. [PMID: 26933849 DOI: 10.1056/nejmoa1505067] [Cited by in Crossref: 209] [Cited by in F6Publishing: 76] [Article Influence: 41.8] [Reference Citation Analysis]
98 Jain A, Dubashi B, Reddy KS, Jain P. Weekly paclitaxel in ovarian cancer-the latest success story. Curr Oncol 2011;18:16-7. [PMID: 21331277 DOI: 10.3747/co.v18i1.680] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
99 Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, Hortobagyi GN, Smith BD, Giordano SH. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol 2014;32:2010-7. [PMID: 24868022 DOI: 10.1200/JCO.2013.49.3676] [Cited by in Crossref: 75] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
100 Luo R, Niu L, Qiu F, Fang W, Fu T, Zhao M, Zhang YJ, Hua ZC, Li XF, Wang F. Monitoring Apoptosis of Breast Cancer Xenograft After Paclitaxel Treatment With 99mTc-Labeled Duramycin SPECT/CT. Mol Imaging 2016;15:1536012115624918. [PMID: 27030401 DOI: 10.1177/1536012115624918] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
101 Sheng JY, Santa-Maria CA, Mangini N, Norman H, Couzi R, Nunes R, Wilkinson M, Visvanathan K, Connolly RM, Roussos Torres ET, Fetting JH, Armstrong DK, Tao JJ, Jacobs L, Wright JL, Thorner ED, Hodgdon C, Horn S, Wolff AC, Stearns V, Smith KL. Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. JCO Oncol Pract 2020;16:665-74. [PMID: 32603252 DOI: 10.1200/OP.20.00364] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
102 Freidlin B, Korn EL. Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions? J Natl Cancer Inst 2017;109. [PMID: 28954288 DOI: 10.1093/jnci/djx146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
103 Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2015;33:442-7. [PMID: 25547504 DOI: 10.1200/JCO.2014.57.1745] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
104 Kim JY, Park S, Im SA, Kim SB, Sohn J, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH, Park YH; Korean Cancer Study Group. Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11). Cancer Commun (Lond) 2019;39:29. [PMID: 31138332 DOI: 10.1186/s40880-019-0375-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Cadoo KA, Kaufman PA, Seidman AD, Chang C, Xing D, Traina TA. Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Clin Breast Cancer 2018;18:433-440.e1. [PMID: 29895438 DOI: 10.1016/j.clbc.2018.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
106 Zhao Z, Li Y, Liu H, Jain A, Patel PV, Cheng K. Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer. Sci Adv 2020;6:eabb0616. [PMID: 32832636 DOI: 10.1126/sciadv.abb0616] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
107 Tan QW, Luo T, Zheng H, Tian TL, He P, Chen J, Zeng HL, Lv Q. Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial. Chin J Cancer 2017;36:27. [PMID: 28270181 DOI: 10.1186/s40880-017-0196-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
108 Moo TA, Sanford R, Dang C, Morrow M. Overview of Breast Cancer Therapy. PET Clin 2018;13:339-54. [PMID: 30100074 DOI: 10.1016/j.cpet.2018.02.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 50] [Article Influence: 24.0] [Reference Citation Analysis]
109 Sibaud V, Lebœuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, Montastruc M, Eche A, Vigarios E, Dalenc F, Lacouture ME. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 2016;26:427-43. [PMID: 27550571 DOI: 10.1684/ejd.2016.2833] [Cited by in Crossref: 68] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
110 Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA. Critically short telomeres and toxicity of chemotherapy in early breast cancer. Oncotarget 2017;8:21472-82. [PMID: 28423524 DOI: 10.18632/oncotarget.15592] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
111 Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 2010;28:77-82. [PMID: 19901117 DOI: 10.1200/JCO.2009.22.1077] [Cited by in Crossref: 99] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
112 Oneda E, Meriggi F, Zanotti L, Zaina E, Bighè S, Andreis F, Rueda S, Zaniboni A. Innovative Approach for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Pilot Study With the Hilotherm Device, the Poliambulanza Hospital Experience. Integr Cancer Ther 2020;19:1534735420943287. [PMID: 32856475 DOI: 10.1177/1534735420943287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
113 Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013;31:2627-33. [PMID: 23733756 DOI: 10.1200/JCO.2012.44.8738] [Cited by in Crossref: 125] [Cited by in F6Publishing: 62] [Article Influence: 15.6] [Reference Citation Analysis]
114 Wilson FR, Coombes ME, Brezden-Masley C, Yurchenko M, Wylie Q, Douma R, Varu A, Hutton B, Skidmore B, Cameron C. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. Syst Rev 2018;7:191. [PMID: 30428932 DOI: 10.1186/s13643-018-0854-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
115 Loprinzi CL, Hershman DL, Staff N. Neuronal Protection for Chemotherapy Neuropathy Prevention? J Natl Cancer Inst 2020;112:3-4. [PMID: 31093679 DOI: 10.1093/jnci/djz088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gökmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. J Clin Oncol 2019;37:3484-92. [PMID: 31657982 DOI: 10.1200/JCO.19.00693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
117 Steenbruggen TG, van Ramshorst MS, Kok M, Linn SC, Smorenburg CH, Sonke GS. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs 2017;77:1313-36. [PMID: 28616845 DOI: 10.1007/s40265-017-0774-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
118 Byrne CE, Decombe JB, Bingham GC, Remont J, Miller LG, Khalif L, King CT, Hamel K, Bunnell BA, Burow ME, Martin EC. Evaluation of Extracellular Matrix Composition to Improve Breast Cancer Modeling. Tissue Eng Part A 2021;27:500-11. [PMID: 33797977 DOI: 10.1089/ten.TEA.2020.0364] [Reference Citation Analysis]
119 Martín M. nab-Paclitaxel dose and schedule in breast cancer. Breast Cancer Res 2015;17:81. [PMID: 26067995 DOI: 10.1186/s13058-015-0587-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
120 Liedtke C, Thill M, Hanf V, Schütz F; AGO Breast Committee. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014. Breast Care (Basel) 2014;9:189-200. [PMID: 25177261 DOI: 10.1159/000363591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
121 Upshaw JN. Cardio-oncology: protecting the heart from curative breast cancer treatment. Gland Surg 2018;7:350-65. [PMID: 30175052 DOI: 10.21037/gs.2017.11.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Ford H, Gounaris I. Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. Therap Adv Gastroenterol 2015;8:189-205. [PMID: 26136837 DOI: 10.1177/1756283X15585468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
123 Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat 2013;141:429-35. [PMID: 24068539 DOI: 10.1007/s10549-013-2704-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
124 Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL 3rd, Wong SF, Fisch MJ, Lynn Henry N, Albain KS. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). J Natl Cancer Inst 2018;110:669-76. [PMID: 29361042 DOI: 10.1093/jnci/djx259] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
125 Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM; TACT2 Investigators. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol 2017;18:929-45. [PMID: 28600210 DOI: 10.1016/S1470-2045(17)30404-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 8.8] [Reference Citation Analysis]
126 Velasco R, Bruna J. Taxane-Induced Peripheral Neurotoxicity. Toxics 2015;3:152-69. [PMID: 29056655 DOI: 10.3390/toxics3020152] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
127 Ley J, Wildes TM, Daly K, Oppelt P, Adkins D. Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. Med Oncol 2017;34:28. [PMID: 28078561 DOI: 10.1007/s12032-017-0884-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
128 Cardonick E. Pregnancy-associated breast cancer: optimal treatment options. Int J Womens Health. 2014;6:935-943. [PMID: 25395871 DOI: 10.2147/ijwh.s52381] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
129 Weiss A, Bashour SI, Hess K, Thompson AM, Ibrahim NK. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Res 2018;20:27. [PMID: 29661243 DOI: 10.1186/s13058-018-0945-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
130 Nieto Y, Aramendía JM, Espinós J, De la Cruz S, Fernández-Hidalgo O, Santisteban M, Arbea L, Aristu J, Martínez-Monge R, Moreno M, Pina L, Sola J, Zornoza G, Regueira FM. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. Cancer Chemother Pharmacol 2010;65:457-65. [PMID: 19526361 DOI: 10.1007/s00280-009-1049-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
131 Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. J Natl Cancer Inst 2018;110:141-8. [PMID: 29924336 DOI: 10.1093/jnci/djx178] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 22.5] [Reference Citation Analysis]
132 Kurian AW, Lichtensztajn DY, Keegan TH, Leung RW, Shema SJ, Hershman DL, Kushi LH, Habel LA, Kolevska T, Caan BJ, Gomez SL. Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat 2013;137:247-60. [PMID: 23139057 DOI: 10.1007/s10549-012-2329-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
133 Tezuka K, Miura K, Nakano Y, Ueda T, Yagyu K, Matsuyama S, Shirai M, Okuda H, Ujikawa M, Ota T. Interstitial lung disease associated with adjuvant and neoadjuvant chemotherapy in early breast cancer. World J Surg Oncol 2021;19:169. [PMID: 34116698 DOI: 10.1186/s12957-021-02289-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Cho E, Wu Q, Rubinstein L, Linden H, Gralow J, Specht J, Gadi V, Ellis G. Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer. Breast J 2018;24:610-4. [PMID: 29532546 DOI: 10.1111/tbj.13013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Ukita Y, Tsubamoto H, Kato T, Suno S, Shibahara H. A case of primary metastatic glassy cell carcinoma of the uterine cervix that responded to combined docetaxel and carboplatin. Gynecol Oncol Case Rep 2013;6:19-21. [PMID: 24371710 DOI: 10.1016/j.gynor.2013.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
136 Crozier JA, Swaika A, Moreno-Aspitia A. Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines. World J Clin Oncol 2014;5:529-38. [PMID: 25114866 DOI: 10.5306/wjco.v5.i3.529] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
137 Fang CT, Kuo HH, Yuan CJ, Yao JS, Yih LH. Mdivi-1 induces spindle abnormalities and augments taxol cytotoxicity in MDA-MB-231 cells. Cell Death Discov 2021;7:118. [PMID: 34016960 DOI: 10.1038/s41420-021-00495-z] [Reference Citation Analysis]
138 Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 2013;18:132-8. [PMID: 22105895 DOI: 10.1007/s10147-011-0352-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 6.1] [Reference Citation Analysis]
139 Bao T, Seidman AD, Piulson L, Vertosick E, Chen X, Vickers AJ, Blinder VS, Zhi WI, Li Q, Vahdat LT, Dickler MN, Robson ME, Mao JJ. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. Eur J Cancer. 2018;101:12-19. [PMID: 30007894 DOI: 10.1016/j.ejca.2018.06.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
140 Kiba T, Morii N, Takahashi H, Ozaki S, Atsumi M, Masumoto F, Yamashiro H. Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series. Breast Cancer (Dove Med Press) 2015;7:245-50. [PMID: 26357489 DOI: 10.2147/BCTT.S90975] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
141 Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, Jiang G, Vance G, Gardner L, Vatta M, Bai S, Lai D, Koller D, Zhao F, O'Neill A, Smith ML, Railey E, White C, Partridge A, Sparano J, Davidson NE, Foroud T, Sledge GW Jr. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 2015;21:5082-91. [PMID: 26138065 DOI: 10.1158/1078-0432.CCR-15-0586] [Cited by in Crossref: 67] [Cited by in F6Publishing: 40] [Article Influence: 11.2] [Reference Citation Analysis]
142 Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 2015;33:58-64. [PMID: 25422488 DOI: 10.1200/JCO.2014.56.3296] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 8.7] [Reference Citation Analysis]
143 Tam YT, Shin DH, Chen KE, Kwon GS. Poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles containing oligo(lactic acid)8-paclitaxel prodrug: In Vivo conversion and antitumor efficacy. J Control Release 2019;298:186-93. [PMID: 30790593 DOI: 10.1016/j.jconrel.2019.02.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
144 Xie H, Liu J, Yu S, Chen Y, Zheng M, Deng Y, Wang S, Jiang J, Li Y, Li H, Kang H, Zhang C, Zhang GJ, Su F, Cheng A, Wang S. Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study. Adv Ther 2019;36:131-46. [PMID: 30511279 DOI: 10.1007/s12325-018-0841-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
145 He H, Cao Y. Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel. J Pharmacokinet Pharmacodyn 2017;44:491-501. [PMID: 28861682 DOI: 10.1007/s10928-017-9540-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
146 Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394:2084-2095. [PMID: 31791688 DOI: 10.1016/s0140-6736(19)32259-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 17] [Article Influence: 28.0] [Reference Citation Analysis]
147 Schneider BP, Shen F, Gardner L, Radovich M, Li L, Miller KD, Jiang G, Lai D, O'Neill A, Sparano JA, Davidson NE, Cameron D, Gradus-Pizlo I, Mastouri RA, Suter TM, Foroud T, Sledge GW Jr. Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clin Cancer Res. 2017;23:43-51. [PMID: 27993963 DOI: 10.1158/1078-0432.ccr-16-0908] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
148 Srinivasan KN, Rauthan A, Gopal R. Combination therapy of albumin-bound Paclitaxel and Carboplatin as first line therapy in a patient with ovarian cancer. Case Rep Oncol Med 2014;2014:940591. [PMID: 24804130 DOI: 10.1155/2014/940591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
149 Ahmed M, Esposito E. Report from the 37th san antonio breast cancer symposium, 9-13th december 2014, Texas, USA. Ecancermedicalscience 2015;9:508. [PMID: 25729421 DOI: 10.3332/ecancer.2015.508] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
150 Butle A, Joshi A, Noronha V, Prabhash K, Dutt A. Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs. Transl Oncol 2021;14:101111. [PMID: 33993094 DOI: 10.1016/j.tranon.2021.101111] [Reference Citation Analysis]
151 Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Fetting J, Davidson NE. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 2012;118:5937-46. [PMID: 22926690 DOI: 10.1002/cncr.27527] [Cited by in Crossref: 127] [Cited by in F6Publishing: 111] [Article Influence: 14.1] [Reference Citation Analysis]
152 Jackisch C, Lück HJ, Untch M, Bischoff J, Müller V, Schmidt M, Thill M, Kiechle M. Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion. Breast Care (Basel) 2012;7:137-43. [PMID: 22740801 DOI: 10.1159/000338273] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
153 Harris JC, Scully MA, Day ES. Cancer Cell Membrane-Coated Nanoparticles for Cancer Management. Cancers (Basel) 2019;11:E1836. [PMID: 31766360 DOI: 10.3390/cancers11121836] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 19.0] [Reference Citation Analysis]
154 Lal LS, Gerber DL, Lau J, Dana W. Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center. Support Care Cancer 2009;17:1311-5. [PMID: 19184123 DOI: 10.1007/s00520-009-0588-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
155 Leone J, Leone BA, Leone JP. Adjuvant systemic therapy in older women with breast cancer. Breast Cancer (Dove Med Press) 2016;8:141-7. [PMID: 27524919 DOI: 10.2147/BCTT.S110765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
156 Schneeweiss A, Denkert C, Fasching PA, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ. Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice. Geburtshilfe Frauenheilkd 2019;79:605-17. [PMID: 31217629 DOI: 10.1055/a-0887-0285] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
157 Banys-Paluchowski M, Schütz F, Ruckhäberle E, Krawczyk N, Fehm T. Metronomic Chemotherapy for Metastatic Breast Cancer - a Systematic Review of the Literature. Geburtshilfe Frauenheilkd 2016;76:525-34. [PMID: 27239061 DOI: 10.1055/s-0042-105871] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
158 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
159 Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 2012;30:2179-82. [PMID: 22614986 DOI: 10.1200/JCO.2012.42.0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
160 Li E, Mezzio DJ, Campbell D, Campbell K, Lyman GH. Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncol Pract 2021;17:e1235-45. [PMID: 33793342 DOI: 10.1200/OP.20.01047] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
161 Tanabe Y, Tsuda H, Yoshida M, Yunokawa M, Yonemori K, Shimizu C, Yamamoto S, Kinoshita T, Fujiwara Y, Tamura K. Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. Cancer Sci 2017;108:1520-9. [PMID: 28474753 DOI: 10.1111/cas.13274] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
162 Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int 2010;107:85-91. [PMID: 20204119 DOI: 10.3238/arztebl.2010.0085] [Cited by in Crossref: 10] [Cited by in F6Publishing: 34] [Article Influence: 0.9] [Reference Citation Analysis]
163 Kang YK, Si YR, An GY, Yuan P. Efficacy and safety of cyclophosphamide in anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer: a meta-analysis. Gland Surg 2021;10:252-61. [PMID: 33633981 DOI: 10.21037/gs-20-593] [Reference Citation Analysis]
164 Foulon A, Theret P, Rodat-Despoix L, Kischel P. Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. Cancers (Basel) 2020;12:E2634. [PMID: 32947780 DOI: 10.3390/cancers12092634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Hyun H, Park MH, Jo G, Lee BY, Choi JW, Chun HJ, Kim HS, Yang DH. Injectable Glycol Chitosan Hydrogel Containing Folic Acid-Functionalized Cyclodextrin-Paclitaxel Complex for Breast Cancer Therapy. Nanomaterials (Basel) 2021;11:317. [PMID: 33513732 DOI: 10.3390/nano11020317] [Reference Citation Analysis]
166 Smyth LM, Iyengar NM, Chen MF, Popper SM, Patil S, Wasserheit-Lieblich C, Argolo DF, Singh JC, Chandarlapaty S, Sugarman SM, Comen EA, Drullinsky PR, Traina TA, Troso-Sandoval T, Baselga J, Norton L, Hudis CA, Dang CT. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res Treat 2016;158:91-7. [PMID: 27306421 DOI: 10.1007/s10549-016-3851-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
167 Möbus V. Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients. Breast Care (Basel) 2016;11:8-12. [PMID: 27051389 DOI: 10.1159/000444004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
168 Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, Eggemann H, Nekljudova V, Sommer H, Kiechle M, Kümmel S. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res 2008;10:R77. [PMID: 18796139 DOI: 10.1186/bcr2144] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
169 Saito Y, Takekuma Y, Kobayashi M, Sakamoto T, Yamashita H, Sugawara M. Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis. Support Care Cancer 2021. [PMID: 34228171 DOI: 10.1007/s00520-021-06342-2] [Reference Citation Analysis]
170 Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast 2015;24 Suppl 2:S149-53. [PMID: 26299406 DOI: 10.1016/j.breast.2015.07.035] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 13.3] [Reference Citation Analysis]
171 Lohmann AE, Speers CH, Chia SK. Evaluation of the clinical benefits of nanoparticle albumin-bound paclitaxel in women with metastatic breast cancer in British Columbia. Curr Oncol 2013;20:97-103. [PMID: 23559872 DOI: 10.3747/co.20.1256] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
172 Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE, Sparano JA. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 2012;30:3051-7. [PMID: 22851566 DOI: 10.1200/JCO.2011.39.8446] [Cited by in Crossref: 59] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
173 Tozuka K, Horiguchi J, Takata D, Rokutanda N, Nagaoka R, Tokiniwa H, Kikuchi M, Satou A, Takei H, Takeyoshi I. Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer. Mol Clin Oncol 2013;1:93-9. [PMID: 24649129 DOI: 10.3892/mco.2012.4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
174 Nagao S, Yamamoto K, Oishi T, Yamaguchi S, Takehara K, Shimada M, Kigawa J. Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer. Int J Clin Oncol 2021;26:207-15. [PMID: 32960420 DOI: 10.1007/s10147-020-01787-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Ardolino L, Lau B, Wilson I, Chen J, Borella L, Stone E, Lim E. Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review. Front Oncol 2021;11:701424. [PMID: 34249762 DOI: 10.3389/fonc.2021.701424] [Reference Citation Analysis]
176 Tesch ME, Chia SK, Simmons CE, LeVasseur N. Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients. Breast Cancer Res Treat 2021;187:167-76. [PMID: 33611678 DOI: 10.1007/s10549-021-06110-0] [Reference Citation Analysis]
177 Puhalla S, Brufsky A. Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer. Biologics 2008;2:505-15. [PMID: 19707381 DOI: 10.2147/btt.s3539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
178 de Castro Baccarin AL, Irene MN, de Iracema Gomes Cubero D, Luz AS, Castro SN, Sordi R, Móz LES, Del Giglio A. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients. Support Care Cancer 2019;27:927-31. [PMID: 30069696 DOI: 10.1007/s00520-018-4381-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
179 Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res 2014;6:253-9. [PMID: 24904223 DOI: 10.2147/CMAR.S40601] [Cited by in Crossref: 77] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
180 Dörfel S, Steffens CC, Meyer D, Tesch H, Kruggel L, Frank M, Jänicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study. Breast Cancer 2018;25:275-83. [PMID: 29204847 DOI: 10.1007/s12282-017-0823-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
181 Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat 2013;139:411-9. [PMID: 23649189 DOI: 10.1007/s10549-013-2552-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
182 Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 2015;33:2353-60. [PMID: 26077235 DOI: 10.1200/JCO.2015.60.9271] [Cited by in Crossref: 110] [Cited by in F6Publishing: 47] [Article Influence: 18.3] [Reference Citation Analysis]
183 McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res 2011;17:3398-407. [PMID: 21350003 DOI: 10.1158/1078-0432.CCR-10-1969] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
184 Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA Oncol 2018;4:302-8. [PMID: 29327055 DOI: 10.1001/jamaoncol.2017.4612] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 21.0] [Reference Citation Analysis]
185 Jin Y, Wang Y, Zhang J, Xiao X, Zhang Q. Efficacy and Safety of Acupuncture against Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2020;2020:8875433. [PMID: 33224260 DOI: 10.1155/2020/8875433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Yoshihara Y, Itoh M, Nobeyama Y, Nakagawa H. A Case of Advanced Extramammary Paget's Disease Successfully Controlled by Monthly but Not Weekly Docetaxel Chemotherapy. Case Rep Oncol 2016;9:6-10. [PMID: 26933412 DOI: 10.1159/000443234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
187 Gandhi S, Fletcher GG, Eisen A, Mates M, Freedman OC, Dent SF, Trudeau ME. Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol 2015;22:S82-94. [PMID: 25848343 DOI: 10.3747/co.22.2321] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
188 Sonnenblick A, Eleyan F, Peretz T, Ospovat I, Merimsky O, Sella T, Peylan-Ramu N, Katz D. Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas. Mol Clin Oncol 2015;3:829-32. [PMID: 26171190 DOI: 10.3892/mco.2015.545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
189 Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305:1873-81. [PMID: 21558518 DOI: 10.1001/jama.2011.593] [Cited by in Crossref: 394] [Cited by in F6Publishing: 328] [Article Influence: 39.4] [Reference Citation Analysis]
190 Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 2013;119:1140-8. [PMID: 23065954 DOI: 10.1002/cncr.27819] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 12.7] [Reference Citation Analysis]
191 Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata H, Mukai H, Uemura Y, Ohashi Y. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer 2017;123:759-68. [PMID: 28081304 DOI: 10.1002/cncr.30421] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
192 Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, Xanthakis I, Christodoulou C, Koutras A, Papandreou CN, Papakostas P, Miliaras S, Markopoulos C, Dimitrakakis C, Korantzopoulos P, Karanikiotis C, Bafaloukos D, Kosmidis P, Samantas E, Varthalitis I, Pavlidis N, Pectasides D, Dimopoulos MA. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer 2014;14:515. [PMID: 25026897 DOI: 10.1186/1471-2407-14-515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
193 Ramirez G, Proctor AR, Jung KW, Wu TT, Han S, Adams RR, Ren J, Byun DK, Madden KS, Brown EB, Foster TH, Farzam P, Durduran T, Choe R. Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy. Biomed Opt Express 2016;7:3610-30. [PMID: 27699124 DOI: 10.1364/BOE.7.003610] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
194 Bacinschi XE, Anghel RM, Toma PI, Safta I, Ilie A, Ilie SM. Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer. Cancer Manag Res 2020;12:1419-26. [PMID: 32161494 DOI: 10.2147/CMAR.S234527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Ginés J, Sabater E, Martorell C, Grau M, Monroy M, Casado MA. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin Transl Oncol 2011;13:485-98. [PMID: 21775276 DOI: 10.1007/s12094-011-0686-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
196 Crake RLI, Strother MR, Phillips E, Doogue MP, Zhang M, Frampton CMA, Robinson BA, Currie MJ. Influence of serum inflammatory cytokines on cytochrome P450 drug metabolising activity during breast cancer chemotherapy: a patient feasibility study. Sci Rep 2021;11:5648. [PMID: 33707475 DOI: 10.1038/s41598-021-85048-1] [Reference Citation Analysis]
197 Resende U, Cabello C, Ramalho SOB, Zeferino LC. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response. BMC Cancer 2019;19:601. [PMID: 31208353 DOI: 10.1186/s12885-019-5812-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
198 Vetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, Güth U, Rochlitz C, Zanetti-Dällenbach R. Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience. Oncotarget 2017;8:75617-26. [PMID: 29088896 DOI: 10.18632/oncotarget.18118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
199 Zeichner SB, Terawaki H, Gogineni K. A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) 2016;10:25-36. [PMID: 27042088 DOI: 10.4137/BCBCR.S32783] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
200 Eisen A, Fletcher GG, Gandhi S, Mates M, Freedman OC, Dent SF, Trudeau ME; members of the Early Breast Cancer Systemic Therapy Consensus Panel. Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. Curr Oncol 2015;22:S67-81. [PMID: 25848340 DOI: 10.3747/co.22.2320] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
201 Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-2966. [PMID: 25071121 DOI: 10.1200/jco.2013.55.0491] [Cited by in Crossref: 655] [Cited by in F6Publishing: 383] [Article Influence: 109.2] [Reference Citation Analysis]
202 Wang R, Smyth LM, Iyengar N, Chandarlapaty S, Modi S, Jochelson M, Patil S, Norton L, Hudis CA, Dang CT. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Oncologist 2019;24:e646-52. [PMID: 30602614 DOI: 10.1634/theoncologist.2018-0512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
203 Fleeman N, Bagust A, Beale S, Dwan K, Dickson R, Proudlove C, Dundar Y. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer. Pharmacoeconomics 2015;33:13-23. [PMID: 25138171 DOI: 10.1007/s40273-014-0206-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
204 Poklepovic A, Qu Y, Dickinson M, Kontos MC, Kmieciak M, Schultz E, Bandopadhyay D, Deng X, Kukreja RC. Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. Cardiooncology 2018;4:7. [PMID: 30221011 DOI: 10.1186/s40959-018-0033-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
205 López-Tarruella S, Martín M. Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res 2009;11:204. [PMID: 19344489 DOI: 10.1186/bcr2226] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
206 Abu Samaan TM, Samec M, Liskova A, Kubatka P, Büsselberg D. Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer. Biomolecules 2019;9:E789. [PMID: 31783552 DOI: 10.3390/biom9120789] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 23.0] [Reference Citation Analysis]
207 Holmes FA, Hellerstedt BA, Pippen JE Jr, Vukelja SJ, Collea RP, Kocs DM, Blum JL, McIntyre KJ, Barve MA, Brooks BD, Osborne CR, Wang Y, Asmar L, O'Shaughnessy J. Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer. Cancer Med 2018;7:2288-98. [PMID: 29582557 DOI: 10.1002/cam4.1472] [Cited by in F6Publishing: 1] [Reference Citation Analysis]